Answers are grounded in this paper and cite their sources.
Background and Aims: Optimal sequencing of therapy in Crohn’s disease (CD) after anti-tumor necrosis factor (TNF) failure remains uncertain. We compared the real-world effectiveness and safety of vedolizumab (VDZ) and ustekinumab (UST) in this setting. Materials and Methods: This retrospective multicenter cohort included 482 patients with moderate-to-severe CD from 14 tertiary centers in Turkey who received VDZ (n = 247) or UST (n = 235) after ≥1 anti-TNF. Clinical remission (CR; Harvey–Bradshaw Index <5) and steroid-free CR (SFCR) at weeks 14 and 52 were primary outcomes. Long-term response, treatment persistence, and safety were also assessed using inverse probability of treatment weighting. Results: At week 14, UST showed higher CR [adjusted odds ratio (aOR) = 1.49, 95% CI: 1.15-1.94] and SFCR (aOR = 1.42, 95% CI: 1.10-1.83) than VDZ. Superiority persisted in patients with prior biological exposure, though outcomes were similar among those with ≥2 biologics. At weeks 52 and 104, CR and SFCR rates were comparable between groups. Treatment persistence was significantly greater with UST (78.5% vs. 53.1% after inverse probability of treatment weighting; aOR = 3.22, 95% CI: 2.43-4.27), and secondary loss of response was lower (14.5% vs. 38.5%, P < 0.001). Adverse events were infrequent and similar across groups, with few serious events. Conclusions: In anti-TNF–experienced CD, UST provided superior early remission and higher treatment persistence compared with VDZ, while long-term efficacy and safety were similar. UST may be favored where rapid disease control and treatment durability are required, though both agents remain important therapeutic options.
No takes yet. Share an insight, caveat, or question.
Sezgin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: